BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Visanne Study to Assess Safety in Adolescents

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: Dienogest (Visanne, BAY86-5258)

First Posted Date: 2011-01-26

Last Posted Date: 2015-08-13

Lead Sponsor: Bayer

Target Recruit Count: 111

Registration Number: NCT01283724

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)
Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)
Drug: DPH 50 mg
Drug: Naproxen sodium 440 mg (BAYH6689)

First Posted Date: 2011-01-21

Last Posted Date: 2015-06-08

Lead Sponsor: Bayer

Target Recruit Count: 712

Registration Number: NCT01280591

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

Phase 3

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Placebo
Drug: Best supportive care

First Posted Date: 2011-01-07

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 199

Registration Number: NCT01271712

European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)

Phase 2

Terminated

Conditions: PAD
Infrapopliteal Lesions

Interventions: Device: Cotavance Paclitaxel Coated Balloon
Device: Standard balloon angioplasty

First Posted Date: 2010-12-15

Last Posted Date: 2024-01-30

Lead Sponsor: Bayer

Target Recruit Count: 44

Registration Number: NCT01260870

Locations: 🇦🇹
Medical University, Graz, Austria
🇧🇪
AZ St.-Blasius Hospital, Dendermonde, Belgium
🇨🇭
University Hospital, Zurich, Switzerland

and more 1 locations

Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo
Drug: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid

First Posted Date: 2010-12-13

Last Posted Date: 2013-09-20

Lead Sponsor: Bayer

Target Recruit Count: 172

Registration Number: NCT01258660

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Bayern, Germany

Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: BAY86-5300

First Posted Date: 2010-12-10

Last Posted Date: 2014-10-28

Lead Sponsor: Bayer

Target Recruit Count: 508

Registration Number: NCT01257984

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Levonorgestrel IUD (LCS, BAY86-5028)
Drug: Yasmin (EE30/DRSP, BAY86-5131)

First Posted Date: 2010-12-06

Last Posted Date: 2017-09-25

Lead Sponsor: Bayer

Target Recruit Count: 567

Registration Number: NCT01254292

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Columbus Center for Women's Health Research, Columbus, Ohio, United States
🇦🇹
Dr. Walter Paulik, Zeltweg, Austria

and more 44 locations

Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)
Drug: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)
Drug: L-5-MTHF Ca 0.451 mg (Metafolin)

First Posted Date: 2010-12-03

Last Posted Date: 2013-08-07

Lead Sponsor: Bayer

Target Recruit Count: 48

Registration Number: NCT01253174

Locations: 🇩🇪
Scope International, Hamburg, Germany

Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)
Drug: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)
Drug: L-5-MTHF 0.451mg (Metafolin)

First Posted Date: 2010-12-03

Last Posted Date: 2013-08-07

Lead Sponsor: Bayer

Target Recruit Count: 44

Registration Number: NCT01253187

Locations: 🇳🇱
Dinox B.V., Groningen, Netherlands

Combination With Gemcitabine in Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: BAY86-9766+Gemcitabine

First Posted Date: 2010-12-02

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 90

Registration Number: NCT01251640

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy